AI Article Synopsis
- - Galectin-3 (Gal-3) is a biomarker linked to various diseases, particularly for assessing risks after acute myocardial infarction (AMI), which is a type of heart attack, helping doctors improve patient survival and quality of life.
- - In a study of 59 AMI patients, Gal-3 levels were measured within 24 hours of symptom onset, and results showed that higher levels of Gal-3 from the aortic root and femoral/radial artery predicted bad outcomes (major adverse cardiovascular events) at a six-month follow-up.
- - The research found that Gal-3 measurements from the aortic root were more effective in predicting risks than those from other sites, making it a crucial prognostic biomarker
Article Abstract
Background: Galectin-3 (Gal-3) is a biomarker involved in a wide range of diseases including cardiac remodeling following acute myocardial infarction (AMI). Identification of prognostic markers in patients with AMI can guide strategies towards improved survival and quality of life.
Methods: Our study included 59 patients with AMI and a preserved ejection fraction. We determined the Gal-3 plasma concentration within 24 h of chest pain onset from the aortic root, femoral/radial artery, coronary sinus and cubital vein. Major adverse cardiovascular events (MACEs) were evaluated at six months follow-up.
Results: MACE at six months post-AMI was recorded in 20 patients (34%). The Gal-3 plasma concentration from the aortic root and the femoral/radial artery were independent predictors of MACE at six months follow-up after the first AMI (OR 1.228; 95%CI: 1.011-1.491; = 0.038; OR 3.438; 95%CI: 1.275-9.265; = 0.015). ROC analysis identifies the Gal-3 plasma concentration from the aortic root as a better predictor of MACE or death (cut-off ≥ 10.86 ng/mL; AUC 0.858; 95%CI: 0.744-0.973; < 0.001) than Gal-3 plasma concentration from the femoral/radial artery (cut-off ≥ 10.18 ng/mL; AUC 0.742; 95%CI: 0.596-0.888; = 0.006).
Conclusion: the Gal-3 plasma concentration in patients with AMI determined during coronary angiography, especially from the aortic root, within 24 h after chest pain onset is a valuable biomarker of prognosis at six months follow-up.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647840 | PMC |
| http://dx.doi.org/10.3390/diagnostics13213348 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Galectin-3 secreted by triple-negative breast cancer cells regulates T cell function.
Neoplasia
December 2024
Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel; Tel Aviv University, Faculty of Medicine and Health Sciences, Tel Aviv, Israel; Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel; Davidoff Cancer Center, Beilinson Campus, Petah Tikva, Israel. Electronic address:
Triple-negative breast cancer (TNBC) is an aggressive subtype that accounts for 10-15 % of breast cancer. Current treatment of high-risk early-stage TNBC includes neoadjuvant chemo-immune therapy. However, the substantial variation in immune response prompts an urgent need for new immune-targeting agents.
View Article and Find Full Text PDFEffect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver.
Eur J Pharmacol
December 2024
Galecto Biotech AB, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, SG1 2FX, UK. Electronic address:
Background And Purpose: Galectin-3 (Gal-3) is a pro-fibrotic β-galactoside binding lectin highly expressed in fibrotic liver and implicated in hepatic fibrosis. GB1107 is a novel orally active Gal-3 small molecule inhibitor that has high affinity for Gal-3 >1000-fold selectively over other galectins. The aim of this study was to characterise GB1107 and galectin-3 in vitro and in vivo in the context of fibrosis signalling and liver disease.
View Article and Find Full Text PDFThe prognostic utility of galectin-3 in patients undergoing cardiac surgery: a scoping review.
Biomarkers
November 2024
Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Objective: To review the utility of galectin-3 (Gal-3) as a biomarker for postoperative adverse outcomes in patients undergoing cardiac surgery.
Method: This review was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Electronic database search was conducted in October 2023.
Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury.
Circ Heart Fail
November 2024
School of Medicine, University College Dublin, Ireland (S.D., R.I., J.M.C., P.T.M.).
Background: Worsening renal function (WRF) is common in hospitalized patients being treated for acute heart failure. However, discriminating clinically significant WRF remains challenging. In patients hospitalized with acute heart failure, we evaluated if blood and urine biomarkers of cardiac and kidney dysfunction were associated with adverse outcomes.
View Article and Find Full Text PDFCompound (E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one downregulation of Galectin-3 ameliorates Aβ pathogenesis-induced neuroinflammation in 5 × FAD mice.
Life Sci
November 2024
Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350112, Fujian Province, China. Electronic address:
Article Synopsis
- Alzheimer's disease (AD) is linked to the aggregation of β-amyloid (Aβ) and inflammation, with Galectin-3 (Gal-3) playing a significant role in this process; the study investigates the compound D30 as a dual-target treatment for both Gal-3 and Aβ.
- The research utilized mouse models and various analytical techniques to assess how D30 affects Aβ production, cognitive function, and Gal-3 levels, showing that D30 reduces Aβ aggregation and improves cognitive abilities while decreasing Gal-3.
- The findings highlight the importance of targeting both Gal-3 and Aβ to combat neuroinflammation in AD; D30 shows promise as a new treatment that could help protect synaptic function
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!